AMG National Trust Bank Acquires Shares of 12,326 Neurocrine Biosciences, Inc. $NBIX

Key Points

• AMG National Trust Bank acquired a new stake of 12,326 shares in Neurocrine Biosciences during Q4, valued at about $1.75 million, while institutional investors own roughly 92.6% of the stock.
• Analyst sentiment is generally positive with a consensus rating of "Moderate Buy" and an average target price of $180.45 (1 Strong Buy, 16 Buy, 5 Hold among analysts).
• Neurocrine reported Q4 EPS of $1.88, missing estimates of $2.36, but revenue grew 28.3% to $805.5 million; the stock trades near $128 with a 52-week range of $105.16–$160.18 and a market cap of $12.87 billion.

AMG National Trust Bank acquired a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 12,326 shares of the company's stock, valued at approximately $1,748,000.

Other institutional investors also recently added to or reduced their stakes in the company. Mitsubishi UFJ Trust & Banking Corp boosted its holdings in shares of Neurocrine Biosciences by 1.1% in the 4th quarter. Mitsubishi UFJ Trust & Banking Corp now owns 79,895 shares of the company's stock worth $11,332,000 after acquiring an additional 847 shares in the last quarter. M&T Bank Corp boosted its holdings in shares of Neurocrine Biosciences by 30.4% in the 4th quarter. M&T Bank Corp now owns 4,318 shares of the company's stock worth $613,000 after acquiring an additional 1,007 shares in the last quarter. Ashton Thomas Private Wealth LLC acquired a new position in shares of Neurocrine Biosciences in the 4th quarter worth approximately $219,000. Gray Foundation acquired a new position in shares of Neurocrine Biosciences in the 4th quarter worth approximately $5,361,000. Finally, Pictet Asset Management Holding SA boosted its holdings in shares of Neurocrine Biosciences by 12.0% in the 4th quarter. Pictet Asset Management Holding SA now owns 776,934 shares of the company's stock worth $110,305,000 after acquiring an additional 83,488 shares in the last quarter. 92.59% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

NBIX has been the topic of several recent analyst reports. Wedbush boosted their target price on Neurocrine Biosciences from $151.00 to $166.00 and gave the stock an "outperform" rating in a report on Tuesday, April 7th. Truist Financial reduced their target price on Neurocrine Biosciences from $169.00 to $140.00 and set a "buy" rating on the stock in a report on Tuesday, February 17th. Royal Bank Of Canada reduced their target price on Neurocrine Biosciences from $180.00 to $177.00 and set an "outperform" rating on the stock in a report on Thursday, February 12th. Needham & Company LLC reissued a "buy" rating and issued a $185.00 target price on shares of Neurocrine Biosciences in a report on Monday, April 6th. Finally, Wolfe Research initiated coverage on Neurocrine Biosciences in a report on Tuesday, February 24th. They issued an "outperform" rating and a $160.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and five have given a Hold rating to the company's stock. According to MarketBeat, Neurocrine Biosciences presently has a consensus rating of "Moderate Buy" and an average target price of $180.45.

Neurocrine Biosciences Stock Performance

NASDAQ:NBIX opened at $127.95 on Wednesday. The stock's fifty day moving average price is $130.16 and its two-hundred day moving average price is $137.82. Neurocrine Biosciences, Inc. has a 52-week low of $105.16 and a 52-week high of $160.18. The company has a market cap of $12.87 billion, a price-to-earnings ratio of 27.46, a P/E/G ratio of 0.67 and a beta of 0.35.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last posted its quarterly earnings data on Wednesday, February 11th. The company reported $1.88 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.36 by ($0.48). Neurocrine Biosciences had a return on equity of 16.48% and a net margin of 16.73%.The firm had revenue of $805.50 million for the quarter, compared to analyst estimates of $804.21 million. During the same period in the prior year, the company posted $1.69 EPS. The firm's quarterly revenue was up 28.3% compared to the same quarter last year. On average, equities analysts predict that Neurocrine Biosciences, Inc. will post 6.33 EPS for the current fiscal year.

Neurocrine Biosciences Profile

Neurocrine Biosciences NASDAQ: NBIX is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine's operations encompass drug discovery, clinical development and commercialization activities.

The company's lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.